Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Byrne, Frederika Maria ^a   Cheetham, Sharon ^b   Vickers, Steven ^b   Chapman, Victoria ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b RenaSci Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; CELL STRUCTURE; CHRONIC PAIN; CONTROLLED STUDY; EVOKED RESPONSE; FLUID INTAKE; GLUCOSE BLOOD LEVEL; IMMUNOFLUORESCENCE; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL; SPINAL CORD TRANSSECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT GAIN; ANALGESIA; ANALYSIS; ANIMAL; ANIMAL BEHAVIOR; ANIMAL FOOD; BLOOD; CHEMISTRY; DIABETIC NEUROPATHIES; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENCE MICROSCOPY; GLIA; METABOLISM; NERVE CELL; PAIN; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMAL FEED; ANIMALS; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DIET, HIGH-FAT; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOGLYCEMIC AGENTS; INSULIN; LINAGLIPTIN; MALE; METFORMIN; MICROSCOPY, FLUORESCENCE; NEUROGLIA; NEURONS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PPAR GAMMA; PURINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 84924211596     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/752481     Document Type: Article

References (74)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes-estimates for the year 2000 and projections for 2030," Diabetes Care, vol. 27, no. 5, pp. 1047-1053, 2004.
2. D. Cheng, "Prevalence, predisposition and prevention of type II diabetes," Nutrition & Metabolism, vol. 2, article 29, 2005.
3. P. J. Dyck, K. M. Kratz, J. L. Karnes et al., "The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study," Neurology, vol. 43, no. 4, pp. 817-824, 1993.
4. C. A. Abbott, R. A. Malik, E. R. E. van Ross, J. Kulkarni, and A. J. M. Boulton, "Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U. K.," Diabetes Care, vol. 34, no. 10, pp. 2220-2224, 2011.
5. T. Szkudelski, "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas," Physiological Research, vol. 50, no. 6, pp. 537-546, 2001.
6. A. M. Tan, O. A. Samad, T. Z. Fischer, P. Zhao, A.-K. Persson, and S. G. Waxman, "Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain," The Journal of Neuroscience, vol. 32, no. 20, pp. 6795-6807, 2012.
7. A. Pertovaara, H. Wei, J. Kalmari, and M. Ruotsalainen, "Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties," Experimental Neurology, vol. 167, no. 2, pp. 425-434, 2001.
8. C. J. Woolf and M. W. Salter, "Plasticity and pain: role of the dorsal horn," in Textbook of Pain, S. B. McMahon and M. Koltzenburg, Eds., pp. 91-105, Elsevier Churchill Livingstone, Philadelphia, Pa, USA, 5th edition, 2006.
9. L. Daulhac, C. Mallet, C. Courteix et al., "Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependentmechanisms," Molecular Pharmacology, vol. 70, no. 4, pp. 1246-1254, 2006.
10. M. Tsuda, H. Ueno, A. Kataoka, H. Tozaki-Saitoh, and K. Inoue, "Activation of dorsal horn microglia contributes to diabetesinduced tactile allodynia via extracellular signal-regulated protein kinase signaling," GLIA, vol. 56, no. 4, pp. 378-386, 2008.
11. Z. H. Afsari, W. M. Renno, and E. Adb-El-Basset, "Alteration of glial fibrillary acidic proteins immunoreactivity in astrocytes of the spinal cord diabetic rats," Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology, vol. 291, no. 4, pp. 390-399, 2008.
12. R. Wodarski, A. K. Clark, J. Grist, F. Marchand, and M. Malcangio, "Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats," European Journal of Pain, vol. 13, no. 8, pp. 807-811, 2009.
13. M. J. Reed, K. Meszaros, L. J. Entes et al., "A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat," Metabolism: Clinical and Experimental, vol. 49, no. 11, pp. 1390-1394, 2000.
14. J. Luo, J. Quan, J. Tsai et al., "Nongeneticmouse models of non-insulin-dependent diabetes mellitus," Metabolism: Clinical and Experimental, vol. 47, no. 6, pp. 663-668, 1998.
15. B. L. Guilford, J. M. Ryals, and D. E. Wright, "Phenotypic changes in diabetic neuropathy induced by a high-fat diet in diabetic C57Bl/6 mice," Experimental Diabetes Research, vol. 2011, Article ID 848307, 14 pages, 2011.
16. J. Luo, J. Quan, J. Tsai et al., "Streptozotocin-induced diabetes in fat-fed mice: a new rodent model of non-insulin-dependent diabetes mellitus," Journal of Investigative Medicine, vol. 46, p. 145A, 1998.
17. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, "Combination of high-fat diet-fed and low-dose streptozotocin treated rat: a model for type 2 diabetes and pharmacological screening," Pharmacological Research, vol. 52, no. 4, pp. 313-320, 2005.
18. M. Boric, I. Skopljanac, L. Ferhatovic, A. Jelicic Kadic, A. Banozic, and L. Puljak, "Reduced epidermal thickness, nerve degeneration and increased pain-related behavior in rats with diabetes type 1 and 2," Journal of Chemical Neuroanatomy, vol. 53, pp. 33-40, 2013.
19. J. K. Dang, Y. Wu, H. Cao et al., "Establishment of a rat model of type II diabetic neuropathic pain," Pain Medicine, vol. 15, no. 4, pp. 637-646, 2014.
20. B. Richter, E. Bandeira-Echtler, K. Bergerhoff, C. Clar, and S. H. Ebrahim, "Pioglitazone for type 2 diabetes mellitus," The Cochrane Database of Systematic Reviews, no. 4, Article ID CD006060, 2006.
21. D. J. Drucker and M. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes," The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
22. M. Stumvoll, N. Nurjhan, G. Perriello, G. Dailey, and J. E. Gerich, "Metabolic effects of metformin in non-insulindependent diabetes mellitus," The New England Journal of Medicine, vol. 333, no. 9, pp. 550-554, 1995.
23. C. Kilkenny, W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, "Improving bioscience research reporting: the arrive guidelines for reporting animal research," PLoS Biology, vol. 8, no. 6, Article ID e1000412, 2010.
24. D. R. Sagar, L. E. Staniaszek, B. N. Okine et al., "Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain," Arthritis & Rheumatism, vol. 62, no. 12, pp. 3666-3676, 2010.
25. Ic in diabetes mellitus," The New England Journal of Medicine, vol. 295, no. 8, pp. 417-420, 1976.
26. B. Hocher, C. Reichetzeder, and M. L. Alter, "Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research," Kidney and Blood Pressure Research, vol. 36, no. 1, pp. 65-84, 2012.
27. S. P. Vickers, S. C. Cheetham, G. D. Birminghamet al., "Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals," Clinical Laboratory, vol. 58, no. 7-8, pp. 787-799, 2012.
28. M. Kern, N. Klöting, H. G. Niessen et al., "Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity," PLoS ONE, vol. 7, no. 6, Article ID e38744, 2012.
29. O. K. Melemedjian, M. N. Asiedu, D. V. Tillu et al., "Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain," Molecular Pain, vol. 7, article 70, 2011.
30. H. Jia, S. Zhu, Q. Ji et al., "Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain," Experimental and Clinical Psychopharmacology, vol. 18, no. 4, pp. 359-365, 2010.
31. S. Iwai, T. Maeda, N. Kiguchi et al., "Pioglitazone attenuates tactile allodynia and microglial activation in mice with peripheral nerve injury," Drug Discoveries & Therapeutics, vol. 2, pp. 353-356, 2008.
32. J. Morgenweck, R. B. Griggs, R. R. Donahue, J. E. Zadina, and B. K. Taylor, "PPARγ activation blocks development and reduces established neuropathic pain in rats," Neuropharmacology, vol. 70, pp. 236-246, 2013.
33. S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung, and T. L. Yaksh, "Quantitative assessment of tactile allodynia in the rat paw," Journal of Neuroscience Methods, vol. 53, no. 1, pp. 55-63, 1994.
34. G. J. Hathway, D. Vega-Avelaira, A. Moss, R. Ingram, and M. Fitzgerald, "Brief, low frequency stimulation of rat peripheral C-fibres evokes prolonged microglial-induced central sensitization in adults but not in neonates," Pain, vol. 144, no. 1-2, pp. 110-118, 2009.
35. M. Pekny and M. Pekna, "Astrocyte intermediate filaments in CNS pathologies and regeneration," Journal of Pathology, vol. 204, no. 4, pp. 428-437, 2004.
36. E. Coleman, R. Judd, L. Hoe, J. Dennis, and P. Posner, "Effects of diabetesmellitus on astrocyte GFAP and glutamate transporters in the CNS," GLIA, vol. 48, no. 2, pp. 166-178, 2004.
37. J. Kim, E. Sohn, C.-S. Kim, Y. M. Lee, K. Jo, and J. S. Kim, "Effect of KIOM-79 on diabetes-induced myocardial fibrosis in Zucker diabetic fatty rats," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 547653, 8 pages, 2013.
38. S. Skovsø, "Modeling type 2 diabetes in rats using high fat diet and streptozotocin," Journal of Diabetes Investigation, vol. 5, no. 4, pp. 349-358, 2014.
39. L. Ferhatovic, A. Banozic, S. Kostic et al., "Expression of calcium/calmodulin-dependent protein kinase II and painrelated behavior in rat models of type 1 and type 2 diabetes," Anesthesia & Analgesia, vol. 116, no. 3, pp. 712-721, 2013.
40. I. G. Obrosova, "Diabetic painful and insensate neuropathy: pathogenesis and potential treatments," Neurotherapeutics, vol. 6, no. 4, pp. 638-647, 2009.
41. S. Hong, T. J. Morrow, P. E. Paulson, L. L. Isom, and J. W. Wiley, "Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat," Journal of Biological Chemistry, vol. 279, no. 28, pp. 29341-29350, 2004.
42. M. Hirade, H. Yasuda, M. Omatsu-Kanbe, R. Kikkawa, and H. Kitasato, "Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats," Neuroscience, vol. 90, no. 3, pp. 933-939, 1999.
43. G. Boden and G. I. Shulman, "Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction," European Journal of Clinical Investigation, vol. 32, no. supplement s3, pp. 14-23, 2002.
44. X. Yi, S. Cao, B. Chang et al., "Effects of acute exercise and chronic exercise on the liver leptin-AMPK-ACC signaling pathway in rats with type 2 diabetes," Journal of Diabetes Research, vol. 2013, Article ID 946432, 9 pages, 2013.
45. Z. Zhang, H.-L. Xue, Y. Liu, and W.-J. Wang, "Yi-Qi-Zeng-Min-Tang, a Chinesemedicine, ameliorates insulin resistance in type 2 diabetic rats," World Journal of Gastroenterology, vol. 17, no. 8, pp. 987-995, 2011.
46. I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov et al., "High-fat diet-induced neuropathy of pre-diabetes and obesity: effects of 'healthy' diet and aldose reductase inhibition," Diabetes, vol. 56, no. 10, pp. 2598-2608, 2007.
47. L. M. Tracy, F. Bergqvist, E. V. Ivanova, K. T. Jacobsen, and K. Iverfeldt, "Exposure to the saturated free fatty acid palmitate alters BV-2 microglia inflammatory response," Journal of Molecular Neuroscience, vol. 51, no. 3, pp. 805-812, 2013.
48. C. Kappe, Q. Zhang, T. Nyström, and Å. Sjöholm, "Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells," Diabetology & Metabolic Syndrome, vol. 6, article 70, 2014.
49. G. Derosa, A. Bonaventura, L. Bianchi et al., "Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients," Metabolism, vol. 63, pp. 957-967, 2014.
50. M. Kusunoki, D. Sato, T. Nakamura et al., "DPP-4 inhibitor teneligliptin improves insulin resistance and serumlipid profile in Japanese patients with type 2 diabetes," Drug Research, 2014.
51. V. Chapman, R. Suzuki, and A. H. Dickenson, "Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6," The Journal of Physiology, vol. 507, no. 3, pp. 881-894, 1998.
52. J. P. Cata, H.-R. Weng, and P. M. Dougherty, "Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy," Brain Research, vol. 1230, pp. 91-98, 2008.
53. L. P. Vera-Portocarrero, E.-T. Zhang, M. H. Ossipov et al., "Descending facilitation fromthe rostral ventromedial medulla maintains nerve injury-induced central sensitization," Neuroscience, vol. 140, no. 4, pp. 1311-1320, 2006.
54. V. Chapman, J. Ng, and A. H. Dickenson, "A novel spinal action of mexiletine in spinal somatosensory transmission of nerve injured rats," Pain, vol. 77, no. 3, pp. 289-296, 1998.
55. Z. Li, J. Wang, L. Chen, M. Zhang, and Y. Wan, "Basolateral amygdala lesion inhibits the development of pain chronicity in neuropathic pain rats," PLoS ONE, vol. 8, no. 8, Article ID e70921, 2013.
56. Y.-J. Gao and R.-R. Ji, "Chemokines, neuronal-glial interactions, and central processing of neuropathic pain," Pharmacology and Therapeutics, vol. 126, no. 1, pp. 56-68, 2010.
57. Y. H. Liao, G. H. Zhang, D. Jia et al., "Spinal astrocytic activation contributes tomechanical allodynia in a mousemodel of type 2 diabetes," Brain Research, vol. 1368, pp. 324-335, 2011.
58. K.-I. Cheng, H.-C. Wang, Y.-T. Chuang et al., "Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased P-p38 mitogen-activated protein kinase activation in streptozotocin-induced diabetic rats," European Journal of Pain, vol. 18, no. 2, pp. 162-173, 2014.
59. E. S. Coleman, J. C. Dennis, T. D. Braden, R. L. Judd, and P. Posner, "Insulin treatment prevents diabetes-induced alterations in astrocyte glutamate uptake and GFAP content in rats at 4 and 8 weeks of diabetes duration," Brain Research, vol. 1306, pp. 131-141, 2010.
60. T. Nakagawa and S. Kaneko, "Spinal astrocytes as therapeutic targets for pathological pain," Journal of Pharmacological Sciences, vol. 114, no. 4, pp. 347-353, 2010.
61. Y. Aizenman and J. de Vellis, "Synergistic action of thyroid hormone, insulin and hydrocortisone on astrocyte differentiation," Brain Research, vol. 414, no. 2, pp. 301-308, 1987.
62. D. Romanovsky, N. F. Cruz, G. A. Dienel, and M. Dobretsov, "Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats," Neurobiology of Disease, vol. 24, no. 2, pp. 384-394, 2006.
63. N. A. Calcutt, M. C. Jorge, T. L. Yaksh, and S. R. Chaplan, "Tactile allodynia and formalin hyperalgesia in streptozotocin diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine," Pain, vol. 68, no. 2-3, pp. 293-299, 1996.
64. R. Bianchi, I. Cervellini, C. Porretta-Serapiglia et al., "Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin induced diabetic peripheral neuropathy," Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 1, pp. 64-72, 2012.
65. H. Y. Jin, W. J. Liu, J. H. Park, H. S. Baek, and T. S. Park, "Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats," Archives of Medical Research, vol. 40, no. 7, pp. 536-544, 2009.
66. T. Himeno, H. Kamiya, K. Naruse et al., "Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice," Diabetes, vol. 60, no. 9, pp. 2397-2406, 2011.
67. S. M. Poucher, S. Cheetham, J. Francis, B. Zinker, M. Kirby, and S. P. Vickers, "Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin induced mouse model of type 2 diabetes," Diabetes, Obesity and Metabolism, vol. 14, no. 10, pp. 918-926, 2012.
68. Q. L. Mao-Ying, A. Kavelaars, K. Krukowski et al., "The anti-diabetic drug metformin protects against chemotherapyinduced peripheral neuropathy in a mouse model," PLoS ONE, vol. 9, no. 6, Article ID e100701, 2014.
69. J. E. Torres-López, M. I. Ortiz, G. Castaeda-Hernández, R. Alonso-López, R. Asomoza-Espinosa, and V. Granados-Soto, "Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test," Life Sciences, vol. 70, no. 14, pp. 1669-1676, 2002.
70. L. Jiménez-Díaz, S. M. Géranton, G. M. Passmore et al., "Local translation in primary afferent fibers regulates nociception," PLoS ONE, vol. 3, no. 4, Article ID e1961, 2008.
71. v1.7 and alters its gating properties," The Journal of Neuro science, vol. 30, no. 5, pp. 1637-1647, 2010.
72. A. Maida, B. J. Lamont, X. Cao, and D. J. Drucker, "Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice," Diabetologia, vol. 54, no. 2, pp. 339-349, 2011.
73. J. C. Fehrenbacher, J. LoVerme, W. Clarke, K. M. Hargreaves, D. Piomelli, and B. K. Taylor, "Rapid painmodulation with nuclear receptor ligands," Brain Research Reviews, vol. 60, no. 1, pp. 114-124, 2009.
74. J. B. Majithiya, A. N. Paramar, and R. Balaraman, "Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats," Cardiovascular Research, vol. 66, no. 1, pp. 150-161, 2005.